furosemide has been researched along with Weight Loss in 46 studies
Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.
furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.
Weight Loss: Decrease in existing BODY WEIGHT.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the effects of different dosing schemes of furosemide on acute heart failure (AHF)." | 9.22 | Comparison of Different Furosemide Regimens in the Treatment of Acute Heart Failure: A Meta-Analysis. ( Chen, D; Guo, F; Huang, J; Huang, Y; Lin, H, 2022) |
| "Despite the heterogeneity and bias in our study, the combination of HSS with furosemide is promising in patients with acute heart failure." | 9.22 | Effect of Hypertonic Saline Solution Combined with Furosemide on Acute Heart Failure: A Meta-Analysis. ( Li, H; Li, Z; Liu, N; Wang, Z, 2022) |
| "The Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan database was examined to assess the short-term clinical course of patients hospitalized with heart failure and hyponatremia and the effect of tolvaptan on outcomes." | 9.17 | Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. ( Burnett, J; Gheorghiade, M; Grinfeld, L; Hauptman, PJ; Konstam, MA; Kostic, D; Krasa, HB; Maggioni, A; Ouyang, J; Swedberg, K; Udelson, JE; Zannad, F; Zimmer, C, 2013) |
| "To evaluate the safety and efficacy of low-dose dopamine, high-dose furosemide, and their combination in the treatment of refractory congestive heart failure." | 9.08 | Increased toxicity of high-dose furosemide versus low-dose dopamine in the treatment of refractory congestive heart failure. ( Cotter, G; Golik, A; Litinski, I; Metzkor, E; Moshkovitz, Y; Perry, C; Tavori, U; Weissgarten, J; Zaidenstein, R, 1997) |
| "We initiated a community-based continuous subcutaneous infusion (CSCI) furosemide service for the treatment of advanced heart failure." | 8.12 | Furosemide in end-stage heart failure: community subcutaneous infusions. ( Armstrong, L; Brown, A; Matthews, I; Ripley, D; Robson, J; Runnett, C; Thomas, H; Westley, K, 2022) |
| "31% of patients had type 2 diabetes mellitus (DM2)." | 7.30 | The use of Dapagliflozin in Acute Decompensated Heart Failure: Results of the Randomized Study. ( Andreev, DA; Charaya, KV; Dimchishina, AS; Kusova, ZR; Mesitskaya, DF; Nikiforova, TV; Novikova, NA; Schekochikhin, DIY; Shkliarov, AM; Soboleva, TV, 2023) |
| "31% of patients had type 2 diabetes mellitus (DM2)." | 7.30 | The use of Dapagliflozin in Acute Decompensated Heart Failure: Results of the Randomized Study. ( Andreev, DA; Charaya, KV; Dimchishina, AS; Kusova, ZR; Mesitskaya, DF; Nikiforova, TV; Novikova, NA; Schekochikhin, DY; Shkliarov, AM; Soboleva, TV, 2023) |
| "To compare the effects of different dosing schemes of furosemide on acute heart failure (AHF)." | 5.22 | Comparison of Different Furosemide Regimens in the Treatment of Acute Heart Failure: A Meta-Analysis. ( Chen, D; Guo, F; Huang, J; Huang, Y; Lin, H, 2022) |
| "Despite the heterogeneity and bias in our study, the combination of HSS with furosemide is promising in patients with acute heart failure." | 5.22 | Effect of Hypertonic Saline Solution Combined with Furosemide on Acute Heart Failure: A Meta-Analysis. ( Li, H; Li, Z; Liu, N; Wang, Z, 2022) |
| "We examined diuretic response (defined as Δ weight kg/40 mg furosemide) in 1745 hospitalized acute heart failure patients from the PROTECT trial." | 5.19 | Diuretic response in acute heart failure: clinical characteristics and prognostic significance. ( Bloomfield, DM; Cleland, JG; Cotter, G; Damman, K; Davison, B; Dittrich, HC; Fiuzat, M; Givertz, MM; Hillege, HL; Massie, BM; Metra, M; O'Connor, CM; Ponikowski, P; Teerlink, JR; Valente, MA; Van Veldhuisen, DJ; Voors, AA, 2014) |
| "The Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan database was examined to assess the short-term clinical course of patients hospitalized with heart failure and hyponatremia and the effect of tolvaptan on outcomes." | 5.17 | Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. ( Burnett, J; Gheorghiade, M; Grinfeld, L; Hauptman, PJ; Konstam, MA; Kostic, D; Krasa, HB; Maggioni, A; Ouyang, J; Swedberg, K; Udelson, JE; Zannad, F; Zimmer, C, 2013) |
| "Our aim was to conduct a meta-analysis to evaluate the efficiency of combination HSS plus furosemide therapy in patients with ADHF in terms of mortality, readmissions, length of hospital stay, kidney function, urine output, body weight, and B-type natriuretic peptide (BNP)." | 5.12 | Efficiency of Hypertonic Saline in the Management of Decompensated Heart Failure: A Systematic Review and Meta-Analysis of Clinical Studies. ( Afsar, B; Copur, S; Covic, A; Kanbay, M; Nistor, I; Siriopol, D; Tapoi, L; Ureche, C, 2021) |
| "Five-day protocolized regimen of 25 g of human serum albumin every 8 hrs with continuous infusion furosemide, or dual placebo, targeted to diuresis, weight loss, and serum total protein." | 5.10 | Albumin and furosemide therapy in hypoproteinemic patients with acute lung injury. ( Bernard, GR; Dupont, WD; Mangialardi, RJ; Martin, GS; Morris, JA; Wheeler, AP, 2002) |
| "Seventy-seven patients received large doses of furosemide (> or = 80 mg/24 h) at some time during the postoperative course, and of these 20 responded poorly to furosemide (weight loss 0." | 5.08 | Addition of a thiazide: an effective remedy for furosemide resistance after cardiac operations. ( Broquist, M; Svedjeholm, R; Vánky, F, 1997) |
| "To evaluate the safety and efficacy of low-dose dopamine, high-dose furosemide, and their combination in the treatment of refractory congestive heart failure." | 5.08 | Increased toxicity of high-dose furosemide versus low-dose dopamine in the treatment of refractory congestive heart failure. ( Cotter, G; Golik, A; Litinski, I; Metzkor, E; Moshkovitz, Y; Perry, C; Tavori, U; Weissgarten, J; Zaidenstein, R, 1997) |
| " Treatment options are serial lumbar punctures combined with body weight reduction as well as medication with carbonic anhydrase inhibitors, such as acetazolamide and topiramate or diuretic therapy with furosemide." | 4.91 | [Characteristic neurological features, differential diagnostic criteria and medicinal treatment of idiopathic intracranial hypertension]. ( Nacimiento, W; Willenborg, KD, 2015) |
| "We initiated a community-based continuous subcutaneous infusion (CSCI) furosemide service for the treatment of advanced heart failure." | 4.12 | Furosemide in end-stage heart failure: community subcutaneous infusions. ( Armstrong, L; Brown, A; Matthews, I; Ripley, D; Robson, J; Runnett, C; Thomas, H; Westley, K, 2022) |
| "A group of 19 patients with advanced disease and severe bilateral leg edema resistant to parenteral diuretic therapy were treated for three days with a combination of multilayer short-stretch compression bandaging and furosemide in hypersaline intravenous infusion." | 3.88 | Diuretics Combined With Compression in Resistant Limb Edema of Advanced Disease-A Case Series Report. ( Gradalski, T, 2018) |
| "A high-performance liquid chromatographic (HPLC) method for the simultaneous analysis of triamterene, trichlormethiazide, furosemide and spironolactone is presented for application in the examination of health food supplements advertising weight reduction and in the analysis of pharmaceuticals." | 3.71 | [Simultaneous analysis of four diuretic drugs by HPLC and its application to health food supplements advertising weight reduction]. ( Goto, T; Matsumoto, H; Mikami, E; Ohno, T, 2002) |
| "Three days of diuretic therapy with furosemide (oral and/or intravenous) for CHF was associated with a measured weight loss of 4." | 3.69 | Bioelectrical impedance analysis as an assessment of diuresis in congestive heart failure. ( Coodley, EL; Neutel, JM; Segal, JL; Smith, DH, 1995) |
| "The effect of furosemide-induced weight loss on the energetic responses of horses to running was examined in a 3-way crossover study." | 3.68 | Effect of furosemide and weight carriage on energetic responses of horses to incremental exertion. ( Hinchcliff, KW; McKeever, KH; Muir, WW; Sams, R, 1993) |
| "31% of patients had type 2 diabetes mellitus (DM2)." | 3.30 | The use of Dapagliflozin in Acute Decompensated Heart Failure: Results of the Randomized Study. ( Andreev, DA; Charaya, KV; Dimchishina, AS; Kusova, ZR; Mesitskaya, DF; Nikiforova, TV; Novikova, NA; Schekochikhin, DIY; Shkliarov, AM; Soboleva, TV, 2023) |
| "31% of patients had type 2 diabetes mellitus (DM2)." | 3.30 | The use of Dapagliflozin in Acute Decompensated Heart Failure: Results of the Randomized Study. ( Andreev, DA; Charaya, KV; Dimchishina, AS; Kusova, ZR; Mesitskaya, DF; Nikiforova, TV; Novikova, NA; Schekochikhin, DY; Shkliarov, AM; Soboleva, TV, 2023) |
| "Weight loss was defined as the difference between baseline and last in-hospital weight." | 2.73 | Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. ( Adams, KF; Califf, RM; Gattis Stough, W; Hasselblad, V; Lokhnygina, Y; O'Connor, CM; Shah, MR, 2007) |
| " On long term evaluation in an open design (Phase II), wherein Phase I participants continued Terminalia Arjuna in fixed dosage (500 mg 8-hourly) in addition to flexible diuretic, vasodilator and digitalis dosage for 20-28 months (mean 24 months) on outpatient basis, patients showed continued improvement in symptoms, signs, effort tolerance and NYHA Class, with improvement in quality of life." | 2.68 | Salutary effect of Terminalia Arjuna in patients with severe refractory heart failure. ( Bharani, A; Bhargava, KD; Ganguly, A, 1995) |
| "Continuous infusion of loop diuretics preceded by a loading dose results in greater diuresis in hospitalized adults with extracellular fluid volume expansion compared with intermittent dosing regimens." | 2.50 | A meta-analysis of continuous vs intermittent infusion of loop diuretics in hospitalized patients. ( Alqahtani, F; Dahal, K; Jaber, BL; Koulouridis, I; Susantitaphong, P, 2014) |
| "The concomitant use of TLV and conventional diuretics is safe and effective for fluid management after TAR using cardiopulmonary bypass, selective cerebral perfusion, and hypothermic circulatory arrest." | 1.51 | Safety and Effectiveness of Tolvaptan Administration after Total Arch Replacement. ( Iida, Y; Shimizu, H; Yoshitake, A, 2019) |
| "To evaluate the effect of administration of the labeled dosage of pimobendan to dogs with furosemide-induced activation of the renin-angiotensin-aldosterone system (RAAS)." | 1.37 | Effects of furosemide and the combination of furosemide and the labeled dosage of pimobendan on the circulating renin-angiotensin-aldosterone system in clinically normal dogs. ( Atkins, CE; DeFrancesco, TC; Keene, BW; Lantis, AC; Werre, SR, 2011) |
| "Symptomatic patent ductus arteriosus (sPDA) may occur in up to 50% of very-low-birth-weight (VLBW, less than or equal to 1500 g) infants." | 1.28 | Symptomatic patent ductus arteriosus in very-low-birth-weight infants: 1987-1989. ( Mouzinho, AI; Risser, R; Rosenfeld, CR, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (26.09) | 18.2507 |
| 2000's | 9 (19.57) | 29.6817 |
| 2010's | 16 (34.78) | 24.3611 |
| 2020's | 9 (19.57) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, Y | 1 |
| Guo, F | 1 |
| Chen, D | 1 |
| Lin, H | 1 |
| Huang, J | 1 |
| Li, Z | 1 |
| Wang, Z | 1 |
| Liu, N | 1 |
| Li, H | 1 |
| Matsumura, Y | 1 |
| Sugiyama, T | 1 |
| Kondo, N | 1 |
| Miyahara, M | 1 |
| Hanaoka, N | 1 |
| Nagashima, H | 1 |
| Kasahara, Y | 1 |
| Fujiyoshi, N | 1 |
| Inada, A | 1 |
| Inaba, S | 1 |
| Charaya, KV | 2 |
| Schekochikhin, DIY | 1 |
| Nikiforova, TV | 2 |
| Dimchishina, AS | 2 |
| Soboleva, TV | 2 |
| Shkliarov, AM | 2 |
| Kusova, ZR | 2 |
| Mesitskaya, DF | 2 |
| Novikova, NA | 2 |
| Andreev, DA | 2 |
| Schekochikhin, DY | 1 |
| Pritchard, A | 1 |
| Spooner, H | 1 |
| Hoffman, R | 1 |
| Brown, A | 1 |
| Westley, K | 1 |
| Robson, J | 1 |
| Armstrong, L | 1 |
| Matthews, I | 1 |
| Runnett, C | 1 |
| Ripley, D | 1 |
| Thomas, H | 1 |
| Covic, A | 1 |
| Copur, S | 1 |
| Tapoi, L | 1 |
| Afsar, B | 1 |
| Ureche, C | 1 |
| Siriopol, D | 1 |
| Nistor, I | 1 |
| Kanbay, M | 1 |
| Piardi, DS | 1 |
| Butzke, M | 1 |
| Mazzuca, ACM | 1 |
| Gomes, BS | 1 |
| Alves, SG | 1 |
| Kotzian, BJ | 1 |
| Ghisleni, EC | 1 |
| Giaretta, V | 1 |
| Bellaver, P | 1 |
| Varaschin, GA | 1 |
| Garbin, AP | 1 |
| Beck-da-Silva, L | 1 |
| Jefferies, JL | 1 |
| DeVita, M | 1 |
| Gradalski, T | 1 |
| Kuriyama, A | 1 |
| Urushidani, S | 1 |
| Iida, Y | 1 |
| Yoshitake, A | 1 |
| Shimizu, H | 1 |
| Alqahtani, F | 1 |
| Koulouridis, I | 1 |
| Susantitaphong, P | 1 |
| Dahal, K | 1 |
| Jaber, BL | 1 |
| Hauptman, PJ | 1 |
| Burnett, J | 1 |
| Gheorghiade, M | 1 |
| Grinfeld, L | 1 |
| Konstam, MA | 1 |
| Kostic, D | 1 |
| Krasa, HB | 1 |
| Maggioni, A | 1 |
| Ouyang, J | 1 |
| Swedberg, K | 1 |
| Zannad, F | 1 |
| Zimmer, C | 1 |
| Udelson, JE | 1 |
| Wu, MY | 1 |
| Chang, NC | 1 |
| Su, CL | 1 |
| Hsu, YH | 1 |
| Chen, TW | 1 |
| Lin, YF | 1 |
| Wu, CH | 1 |
| Tam, KW | 1 |
| Valente, MA | 1 |
| Voors, AA | 1 |
| Damman, K | 1 |
| Van Veldhuisen, DJ | 1 |
| Massie, BM | 1 |
| O'Connor, CM | 3 |
| Metra, M | 1 |
| Ponikowski, P | 1 |
| Teerlink, JR | 1 |
| Cotter, G | 2 |
| Davison, B | 1 |
| Cleland, JG | 1 |
| Givertz, MM | 1 |
| Bloomfield, DM | 1 |
| Fiuzat, M | 1 |
| Dittrich, HC | 1 |
| Hillege, HL | 1 |
| Palazzuoli, A | 1 |
| Pellegrini, M | 1 |
| Ruocco, G | 1 |
| Martini, G | 1 |
| Franci, B | 1 |
| Campagna, MS | 1 |
| Gilleman, M | 1 |
| Nuti, R | 1 |
| McCullough, PA | 1 |
| Ronco, C | 1 |
| Lucisano, G | 1 |
| Simeoni, M | 1 |
| Comi, N | 1 |
| Citraro, ML | 1 |
| Fuiano, L | 1 |
| Fuiano, G | 1 |
| Willenborg, KD | 1 |
| Nacimiento, W | 1 |
| Dharmaraj, R | 1 |
| Hari, P | 1 |
| Bagga, A | 1 |
| Tabak'ian, EA | 1 |
| Zaruba, AIu | 1 |
| Miasnikov, RP | 1 |
| Ataullakhanova, DM | 1 |
| Kukharchuk, VV | 1 |
| Lum, E | 1 |
| Tymchuk, C | 1 |
| Serag, R | 1 |
| Afsarmanesh, N | 1 |
| Lantis, AC | 1 |
| Atkins, CE | 1 |
| DeFrancesco, TC | 1 |
| Keene, BW | 1 |
| Werre, SR | 1 |
| Banerjee, P | 1 |
| Tanner, G | 1 |
| Williams, L | 1 |
| Kociol, RD | 1 |
| McNulty, SE | 1 |
| Hernandez, AF | 1 |
| Lee, KL | 1 |
| Redfield, MM | 1 |
| Tracy, RP | 1 |
| Braunwald, E | 1 |
| Felker, GM | 1 |
| Martin, GS | 1 |
| Mangialardi, RJ | 1 |
| Wheeler, AP | 1 |
| Dupont, WD | 1 |
| Morris, JA | 1 |
| Bernard, GR | 1 |
| Gattinoni, L | 1 |
| Caspani, ML | 1 |
| Coleman, RJ | 1 |
| St Lawrence, AC | 1 |
| Lawrence, LM | 1 |
| Roberts, AM | 1 |
| Sharp, RP | 1 |
| Gregory, A | 1 |
| Mowdy, MH | 1 |
| Sirajuddin, R | 1 |
| Zawadzkas, XA | 1 |
| Sides, RH | 1 |
| Bayly, WM | 1 |
| Hasselblad, V | 1 |
| Gattis Stough, W | 1 |
| Shah, MR | 1 |
| Lokhnygina, Y | 1 |
| Califf, RM | 1 |
| Adams, KF | 1 |
| Bharani, A | 1 |
| Ganguly, A | 1 |
| Bhargava, KD | 1 |
| Hinchcliff, KW | 2 |
| McKeever, KH | 2 |
| Muir, WW | 2 |
| Sams, R | 1 |
| Haws, RM | 1 |
| Baum, M | 1 |
| Coodley, EL | 1 |
| Segal, JL | 1 |
| Smith, DH | 1 |
| Neutel, JM | 1 |
| Vánky, F | 1 |
| Broquist, M | 1 |
| Svedjeholm, R | 1 |
| Weissgarten, J | 1 |
| Metzkor, E | 1 |
| Moshkovitz, Y | 1 |
| Litinski, I | 1 |
| Tavori, U | 1 |
| Perry, C | 1 |
| Zaidenstein, R | 1 |
| Golik, A | 1 |
| O'Brien, C | 1 |
| Young, AJ | 1 |
| Sawka, MN | 1 |
| Goto, T | 1 |
| Mikami, E | 1 |
| Ohno, T | 1 |
| Matsumoto, H | 1 |
| Lax, D | 1 |
| Eicher, M | 1 |
| Goldberg, SJ | 1 |
| Mouzinho, AI | 1 |
| Rosenfeld, CR | 1 |
| Risser, R | 1 |
| Parikh, SS | 1 |
| Amarapurkar, DN | 1 |
| Viswanath, N | 1 |
| Desai, HG | 1 |
| Kalro, RH | 1 |
| de Garavilla, L | 1 |
| Durkot, MJ | 1 |
| Ihley, TM | 1 |
| Leva, N | 1 |
| Francesconi, RP | 1 |
| Coffey, CS | 1 |
| Steiner, D | 1 |
| Baker, BA | 1 |
| Allison, DB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Protocol 156-03-236: Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long Term Efficacy and Safety of Oral Tolvaptan Tablets in Subjects Hospitalized With Worsening Congestive Heart Failure[NCT00071331] | Phase 3 | 3,600 participants | Interventional | 2003-09-30 | Completed | ||
| A Randomized, Open-label Study of Dapagliflozin in Patients With or Without Type 2 Diabetes Admitted With Acute Heart Failure[NCT04298229] | Phase 3 | 240 participants (Actual) | Interventional | 2020-04-01 | Completed | ||
| Continuous Versus Intermittent Loop Diuretics Infusion Dosing in Acute Heart Failure: Effects on Renal Function, Outcome and BNP Levels[NCT01441245] | Phase 4 | 57 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| Continuous Versus Bolus Intermittent Loop Diuretic Infusion in Acutely Decompensated Heart Failure: Evaluation of Renal Function, Congestion Signs, BNP and Outcome[NCT02638142] | 116 participants (Actual) | Observational | 2015-12-31 | Active, not recruiting | |||
| Diuretic Optimal Strategy Evaluation in Acute Heart Failure (The DOSE-AHF Study)[NCT00577135] | Phase 3 | 308 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Remote Dielectric Sensing (ReDS) for a SAFE Discharge in Patients With Acutely Decompensated Heart Failure: The ReDS-SAFE HF Study[NCT04305717] | 240 participants (Anticipated) | Interventional | 2020-08-14 | Recruiting | |||
| Hemodynamics and Extravascular Lung Water in Acute Lung Injury: A Prospective Randomized Controlled Multicentered Trial of Goal Directed Treatment of EVLW Versus Standard Management for the Treatment of Acute Lung Injury[NCT00624650] | Phase 2 | 33 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01441245)
Timeframe: participants were followed for the duration of hospital stay, an average of 13 days
| Intervention | pg/mL (Mean) |
|---|---|
| BNP Change in cIV | -525 |
| BNP Change in iIV | -148 |
(NCT01441245)
Timeframe: in-hospital
| Intervention | percentage of partecipants (Number) |
|---|---|
| Dopamine Infusion in cIV | 50 |
| Dopamine Infusion in iIV | 26 |
(NCT01441245)
Timeframe: from admission to discharge, an average of 12 days
| Intervention | pg/ml (Mean) |
|---|---|
| BNP Levels at Discharge in cIV Group | 679 |
| BNP Levels at Discharge in iIV Group | 949 |
this study aimed to evaluate the effects of continuous infusion of furosemide in comparison to twice daily regimens at similar doses with respect to changes in renal function in terms of creatinine levels and GFR, urine output and BNP levels from admission to discharge (NCT01441245)
Timeframe: time period ranging from 72 h to 120 h.
| Intervention | mL (Mean) |
|---|---|
| Urine Output in cIV | 2505 |
| Urine Output in iIV | 2140 |
evaluation of renal function in terms of changes in creatinine levels during hospitalization in the two arms. (NCT01441245)
Timeframe: participants were followed for the duration of hospital stay, an average of 13 days
| Intervention | mg/dL (Mean) |
|---|---|
| Changes in Creatinine in cIV Group | -0.10 |
| Changes in Creatinine in iIV Group | -0.50 |
(NCT01441245)
Timeframe: from admission to discharge, an average of 12 days
| Intervention | (ml/min·1.73 m2) (Mean) |
|---|---|
| GFR Change in cIV | -3.18 |
| GFR Change in iIV | -1.93 |
(NCT01441245)
Timeframe: from admission to discharge, an average of 12 days
| Intervention | mg/dL (Mean) |
|---|---|
| Creatinine at Discharge in cIV | 1.78 |
| Creatinine at Discharge in iIV | 1.51 |
(NCT01441245)
Timeframe: from admission to discharge, an average of 12 days
| Intervention | (ml/min·1.73 m2) (Mean) |
|---|---|
| GFR at Discharge in cIV | 44.8 |
| GFR at Discharge in iIV | 46.7 |
percentage of participants with hospital stay > 10 days (NCT01441245)
Timeframe: in-hospital
| Intervention | percentage of partecipants (Number) |
|---|---|
| Lenght of Hospitalization in cIV | 80 |
| Lenght of Hospitalization in iIV | 44 |
Change in NTproBNP (NCT00577135)
Timeframe: baseline and 72 hours
| Intervention | pg/mL (Mean) |
|---|---|
| Q 12 Hour Bolus | -1316.2 |
| Continuous Infusion | -1773.2 |
| Low Intensification | -1193.8 |
| High Intensification | -1881.6 |
(NCT00577135)
Timeframe: baseline and 72 hours
| Intervention | mg/L (Mean) |
|---|---|
| Q 12 Hour Bolus | 0.11 |
| Continuous Infusion | 0.17 |
| Low Intensification | 0.12 |
| High Intensification | 0.17 |
(NCT00577135)
Timeframe: baseline and day 60
| Intervention | mg/L (Mean) |
|---|---|
| Q 12 Hour Bolus | 0.20 |
| Continuous Infusion | 0.16 |
| Low Intensification | 0.18 |
| High Intensification | 0.18 |
(NCT00577135)
Timeframe: baseline and day 7
| Intervention | mg/L (Mean) |
|---|---|
| Q 12 Hour Bolus | 0.21 |
| Continuous Infusion | 0.16 |
| Low Intensification | 0.16 |
| High Intensification | 0.21 |
(NCT00577135)
Timeframe: baseline and Day 60
| Intervention | pg/mL (Mean) |
|---|---|
| Q 12 Hour Bolus | -1449.3 |
| Continuous Infusion | -1035.1 |
| Low Intensification | -1445.6 |
| High Intensification | -1038.5 |
(NCT00577135)
Timeframe: baseline and Day 7
| Intervention | pg/mL (Mean) |
|---|---|
| Q 12 Hour Bolus | -1133.3 |
| Continuous Infusion | -1552.0 |
| Low Intensification | -1037.2 |
| High Intensification | -1629.7 |
(NCT00577135)
Timeframe: baseline and 24 hours
| Intervention | mg/dL (Mean) |
|---|---|
| Q 12 Hour Bolus | 0.00 |
| Continuous Infusion | 0.01 |
| Low Intensification | -0.01 |
| High Intensification | 0.02 |
(NCT00577135)
Timeframe: baseline and 48 hours
| Intervention | mg/dL (Mean) |
|---|---|
| Q 12 Hour Bolus | 0.02 |
| Continuous Infusion | 0.05 |
| Low Intensification | 0.01 |
| High Intensification | 0.06 |
(NCT00577135)
Timeframe: baseline and 96 hours
| Intervention | mg/dL (Mean) |
|---|---|
| Q 12 Hour Bolus | 0.06 |
| Continuous Infusion | 0.05 |
| Low Intensification | 0.05 |
| High Intensification | 0.07 |
(NCT00577135)
Timeframe: baseline and day 60
| Intervention | mg/dL (Mean) |
|---|---|
| Q 12 Hour Bolus | 0.09 |
| Continuous Infusion | 0.07 |
| Low Intensification | 0.09 |
| High Intensification | 0.07 |
(NCT00577135)
Timeframe: baseline and day 7
| Intervention | mg/dL (Mean) |
|---|---|
| Q 12 Hour Bolus | 0.10 |
| Continuous Infusion | 0.04 |
| Low Intensification | 0.07 |
| High Intensification | 0.08 |
(NCT00577135)
Timeframe: Measured at baseline and 72 hours
| Intervention | mg/dL (Mean) |
|---|---|
| Q 12 Hour Bolus | 0.05 |
| Continuous Infusion | 0.07 |
| Low Intensification | 0.04 |
| High Intensification | 0.08 |
(NCT00577135)
Timeframe: baseline and 72 hours
| Intervention | mg/dL (Mean) |
|---|---|
| Q 12 Hour Bolus | 0.30 |
| Continuous Infusion | 0.44 |
| Low Intensification | 0.11 |
| High Intensification | 0.61 |
(NCT00577135)
Timeframe: baseline and Day 60
| Intervention | mg/dL (Mean) |
|---|---|
| Q 12 Hour Bolus | -0.09 |
| Continuous Infusion | -0.71 |
| Low Intensification | -0.13 |
| High Intensification | -0.67 |
(NCT00577135)
Timeframe: baseline and day 7
| Intervention | mg/dL (Mean) |
|---|---|
| Q 12 Hour Bolus | 0.40 |
| Continuous Infusion | 0.09 |
| Low Intensification | 0.07 |
| High Intensification | 0.42 |
(NCT00577135)
Timeframe: baseline and 96 hours
| Intervention | lbs (Mean) |
|---|---|
| Q 12 Hour Bolus | -8.0 |
| Continuous Infusion | -9.1 |
| Low Intensification | -7.4 |
| High Intensification | -9.6 |
Dyspnea Visual Analog Scale Scale Range 0-4800; higher score is better (NCT00577135)
Timeframe: 48 hours
| Intervention | units on a scale (Mean) |
|---|---|
| Q 12 Hour Bolus | 2876.6 |
| Continuous Infusion | 3033.1 |
| Low Intensification | 2924.9 |
| High Intensification | 2981.3 |
Dyspnea Visual Analog Scale Scale Range 0-7200; higher score is better (NCT00577135)
Timeframe: 72 hours
| Intervention | units on a scale (Mean) |
|---|---|
| Q 12 Hour Bolus | 4455.6 |
| Continuous Infusion | 4699.1 |
| Low Intensification | 4477.9 |
| High Intensification | 4668.3 |
Global Visual Analog Scale Scale Range 0-2400; higher score is better (NCT00577135)
Timeframe: Measured at 24 hours
| Intervention | units on a scale (Mean) |
|---|---|
| Q 12 Hour Bolus | 1370.8 |
| Continuous Infusion | 1453.8 |
| Low Intensification | 1426.0 |
| High Intensification | 1398.2 |
(NCT00577135)
Timeframe: Through 24 hours
| Intervention | mL (Mean) |
|---|---|
| Q 12 Hour Bolus | 1595.7 |
| Continuous Infusion | 1796.4 |
| Low Intensification | 1209.7 |
| High Intensification | 2149.6 |
(NCT00577135)
Timeframe: Through 48 hours
| Intervention | mL (Mean) |
|---|---|
| Q 12 Hour Bolus | 2996.7 |
| Continuous Infusion | 3120.6 |
| Low Intensification | 2334.8 |
| High Intensification | 3747.4 |
(NCT00577135)
Timeframe: Through 72 hours
| Intervention | mL (Mean) |
|---|---|
| Q 12 Hour Bolus | 4236.7 |
| Continuous Infusion | 4249.2 |
| Low Intensification | 3575.2 |
| High Intensification | 4898.9 |
Global Visual Analog Scale Scale Range 0-2400; higher score is better (NCT00577135)
Timeframe: Measured at 24 hours
| Intervention | units on a scale (Mean) |
|---|---|
| Q 12 Hour Bolus | 1280.8 |
| Continuous Infusion | 1303.0 |
| Low Intensification | 1288.6 |
| High Intensification | 1294.8 |
Global Visual Analog Scale Scale Range 0-4800; higher score is better (NCT00577135)
Timeframe: 48 hours
| Intervention | units on a scale (Mean) |
|---|---|
| Q 12 Hour Bolus | 2722.6 |
| Continuous Infusion | 2792.6 |
| Low Intensification | 2706.5 |
| High Intensification | 2805.2 |
Global Visual Analog Scale Scale Range 0-7200; higher score is better (NCT00577135)
Timeframe: Measured at 72 hours
| Intervention | units on a scale (Mean) |
|---|---|
| Q 12 Hour Bolus | 4236 |
| Continuous Infusion | 4372.7 |
| Low Intensification | 4170.8 |
| High Intensification | 4429.6 |
(NCT00577135)
Timeframe: Within 72 hours
| Intervention | percentage of participants (Number) |
|---|---|
| Q 12 Hour Bolus | 17.4 |
| Continuous Infusion | 19.2 |
| Low Intensification | 13.6 |
| High Intensification | 22.7 |
(NCT00577135)
Timeframe: Measured at 72 hours
| Intervention | percentage of participants (Number) |
|---|---|
| Q 12 Hour Bolus | 14.4 |
| Continuous Infusion | 15.3 |
| Low Intensification | 11.2 |
| High Intensification | 18.2 |
Treatment failure is defined as the patient met cardiorenal syndrome endpoint, worsening or persistent heart failure endpoint, patient died, or there was clinical evidence of overdiuresis requiring intervention within first 72 hours after randomization (NCT00577135)
Timeframe: Within 72 hours
| Intervention | percentage of participants (Number) |
|---|---|
| Q 12 Hour Bolus | 38.1 |
| Continuous Infusion | 38.8 |
| Low Intensification | 36.7 |
| High Intensification | 40.0 |
7 reviews available for furosemide and Weight Loss
| Article | Year |
|---|---|
Comparison of Different Furosemide Regimens in the Treatment of Acute Heart Failure: A Meta-Analysis.
Topics: Furosemide; Heart Failure; Humans; Infusions, Intravenous; Length of Stay; Weight Loss | 2022 |
Effect of Hypertonic Saline Solution Combined with Furosemide on Acute Heart Failure: A Meta-Analysis.
Topics: Creatinine; Diuretics; Furosemide; Heart Failure; Humans; Saline Solution, Hypertonic; Weight Loss | 2022 |
Efficiency of Hypertonic Saline in the Management of Decompensated Heart Failure: A Systematic Review and Meta-Analysis of Clinical Studies.
Topics: Body Weight; Diuresis; Diuretics; Drug Therapy, Combination; Furosemide; Heart Failure; Humans; Kidn | 2021 |
Continuous versus intermittent administration of furosemide in acute decompensated heart failure: a systematic review and meta-analysis.
Topics: Acute Disease; Aged; Aged, 80 and over; Female; Furosemide; Heart Failure; Humans; Male; Middle Aged | 2019 |
A meta-analysis of continuous vs intermittent infusion of loop diuretics in hospitalized patients.
Topics: Adult; Aged; Child; Child, Preschool; Critical Care; Drug Administration Schedule; Furosemide; Hospi | 2014 |
Loop diuretic strategies in patients with acute decompensated heart failure: a meta-analysis of randomized controlled trials.
Topics: Acute Disease; Critical Care; Furosemide; Heart Failure; Hospital Mortality; Humans; Infusions, Intr | 2014 |
[Characteristic neurological features, differential diagnostic criteria and medicinal treatment of idiopathic intracranial hypertension].
Topics: Acetazolamide; Cerebrospinal Fluid Shunts; Combined Modality Therapy; Diagnosis, Differential; Fruct | 2015 |
17 trials available for furosemide and Weight Loss
| Article | Year |
|---|---|
The use of Dapagliflozin in Acute Decompensated Heart Failure: Results of the Randomized Study.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Furosemide; Heart F | 2023 |
The use of Dapagliflozin in Acute Decompensated Heart Failure: Results of the Randomized Study.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Furosemide; Heart F | 2023 |
Effect of adding hydrochlorothiazide to usual treatment of patients with acute decompensated heart failure: a randomized clinical trial.
Topics: Creatinine; Diuretics; Double-Blind Method; Female; Furosemide; Heart Failure; Humans; Hydrochloroth | 2021 |
Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan.
Topics: Aged; Analysis of Variance; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzaze | 2013 |
Diuretic response in acute heart failure: clinical characteristics and prognostic significance.
Topics: Acute Disease; Aged; Analysis of Variance; Atherosclerosis; Bumetanide; Diabetes Complications; Diur | 2014 |
Continuous versus bolus intermittent loop diuretic infusion in acutely decompensated heart failure: a prospective randomized trial.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Creatinine; Diuretics; Double-Blind Method; Female; Fu | 2014 |
Continuous versus bolus intermittent loop diuretic infusion in acutely decompensated heart failure: a prospective randomized trial.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Creatinine; Diuretics; Double-Blind Method; Female; Fu | 2014 |
Continuous versus bolus intermittent loop diuretic infusion in acutely decompensated heart failure: a prospective randomized trial.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Creatinine; Diuretics; Double-Blind Method; Female; Fu | 2014 |
Continuous versus bolus intermittent loop diuretic infusion in acutely decompensated heart failure: a prospective randomized trial.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Creatinine; Diuretics; Double-Blind Method; Female; Fu | 2014 |
Randomized cross-over trial comparing albumin and frusemide infusions in nephrotic syndrome.
Topics: Adolescent; Child; Child, Preschool; Cross-Over Studies; Diuretics; Drug Therapy, Combination; Edema | 2009 |
[Application of methods of renal replacement therapy for abolishment of hyperhydration in patients with decompensated chronic heart failure].
Topics: Adult; Aged; Aged, 80 and over; Diuretics; Edema, Cardiac; Female; Furosemide; Heart Failure; Hemofi | 2010 |
Albumin and furosemide therapy in hypoproteinemic patients with acute lung injury.
Topics: Adult; Blood Proteins; Colloids; Diuresis; Diuretics; Double-Blind Method; Female; Furosemide; Hemod | 2002 |
Is improved high speed performance following frusemide administration due to diuresis-induced weight loss or reduced severity of exercise-induced pulmonary haemorrhage?
Topics: Analysis of Variance; Animals; Bronchoalveolar Lavage Fluid; Cross-Over Studies; Diuretics; Exercise | 2006 |
Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial.
Topics: Aged; Cardiotonic Agents; Databases as Topic; Female; Furosemide; Heart Failure; Hospitalization; Hu | 2007 |
Salutary effect of Terminalia Arjuna in patients with severe refractory heart failure.
Topics: Adult; Aged; Cardiomyopathy, Dilated; Chemotherapy, Adjuvant; Chronic Disease; Coronary Disease; Cro | 1995 |
Addition of a thiazide: an effective remedy for furosemide resistance after cardiac operations.
Topics: Administration, Oral; Aged; Amiloride; Coronary Artery Bypass; Creatinine; Diuretics; Drug Administr | 1997 |
Increased toxicity of high-dose furosemide versus low-dose dopamine in the treatment of refractory congestive heart failure.
Topics: Acute Kidney Injury; Administration, Oral; Aged; Blood Pressure; Diuretics; Dopamine; Drug Therapy, | 1997 |
Hypohydration and thermoregulation in cold air.
Topics: Adult; Blood Volume; Body Temperature Regulation; Cold Temperature; Dehydration; Diuretics; Furosemi | 1998 |
Mild dehydration induces echocardiographic signs of mitral valve prolapse in healthy females with prior normal cardiac findings.
Topics: Adult; Blood Pressure; Body Constitution; Cardiac Output; Dehydration; Double-Blind Method; Echocard | 1992 |
A randomized double-blind placebo-controlled clinical trial of a product containing ephedrine, caffeine, and other ingredients from herbal sources for treatment of overweight and obesity in the absence of lifestyle treatment.
Topics: Adult; Anti-Obesity Agents; Benzyl Alcohols; Body Mass Index; Caffeine; Cola; Double-Blind Method; D | 2004 |
22 other studies available for furosemide and Weight Loss
| Article | Year |
|---|---|
Fluid restriction management in the treatment of COVID-19: a single-center observational study.
Topics: Anticoagulants; COVID-19; Female; Furosemide; Humans; Male; Oxygen; Respiration, Artificial; SARS-Co | 2022 |
Influence of Long-Term Furosemide Use on Bone Mineral Content, Bone Metabolism Markers, and Water Weight Loss in Horses.
Topics: Animals; Bone Density; Furosemide; Horse Diseases; Horses; Lung Diseases; Water; Weight Loss | 2019 |
Furosemide in end-stage heart failure: community subcutaneous infusions.
Topics: Aged; Diuretics; Furosemide; Heart Failure; Humans; Infusions, Subcutaneous; Retrospective Studies; | 2022 |
Diuresis-Related Weight Loss Reflects Interstitial Compartment Decongestion With Minimal Impact on Intravascular Volume Expansion or Outcomes in Post-Acute Heart Failure.
Topics: Diuresis; Furosemide; Heart Failure; Humans; Weight Loss | 2022 |
Diuretics Combined With Compression in Resistant Limb Edema of Advanced Disease-A Case Series Report.
Topics: Aged; Aged, 80 and over; Combined Modality Therapy; Compression Bandages; Disease Management; Diuret | 2018 |
Safety and Effectiveness of Tolvaptan Administration after Total Arch Replacement.
Topics: Administration, Oral; Aged; Antidiuretic Hormone Receptor Antagonists; Aortic Aneurysm, Thoracic; Bl | 2019 |
Continuous intravenous infusion of furosemide is more effective and safer than coadministration of albumin and furosemide in patients with nephrotic syndrome.
Topics: Aged; Albumins; Diuretics; Drug Therapy, Combination; Female; Furosemide; Glomerulonephritis, Membra | 2015 |
Diagnosis by treatment.
Topics: Acquired Immunodeficiency Syndrome; Beriberi; Cardiomyopathies; Colonoscopy; Diarrhea; Dyspnea; Fema | 2011 |
Effects of furosemide and the combination of furosemide and the labeled dosage of pimobendan on the circulating renin-angiotensin-aldosterone system in clinically normal dogs.
Topics: Administration, Oral; Aldosterone; Animals; Bicarbonates; Blood Chemical Analysis; Blood Pressure; C | 2011 |
Intravenous diuretic day-care treatment for patients with heart failure.
Topics: Aged; Aged, 80 and over; Cost Savings; Day Care, Medical; Disease Management; Disease Progression; D | 2012 |
Markers of decongestion, dyspnea relief, and clinical outcomes among patients hospitalized with acute heart failure.
Topics: Acute Disease; Aged; Biomarkers; Chi-Square Distribution; Diuretics; Drug Administration Schedule; D | 2013 |
Markers of decongestion, dyspnea relief, and clinical outcomes among patients hospitalized with acute heart failure.
Topics: Acute Disease; Aged; Biomarkers; Chi-Square Distribution; Diuretics; Drug Administration Schedule; D | 2013 |
Markers of decongestion, dyspnea relief, and clinical outcomes among patients hospitalized with acute heart failure.
Topics: Acute Disease; Aged; Biomarkers; Chi-Square Distribution; Diuretics; Drug Administration Schedule; D | 2013 |
Markers of decongestion, dyspnea relief, and clinical outcomes among patients hospitalized with acute heart failure.
Topics: Acute Disease; Aged; Biomarkers; Chi-Square Distribution; Diuretics; Drug Administration Schedule; D | 2013 |
Albumin and furosemide in acute lung injury: a little step forward?
Topics: Diuresis; Diuretics; Furosemide; Humans; Respiratory Distress Syndrome; Serum Albumin; Weight Loss | 2002 |
Effect of frusemide on bodyweight loss and recovery in racing Standardbreds.
Topics: Acid-Base Equilibrium; Animals; Body Weight; Dehydration; Diuretics; Female; Furosemide; Horse Disea | 2002 |
Nesiritide for treatment of heart failure due to right ventricular dysfunction.
Topics: Adult; Cardiac Output, Low; Diuretics; Furosemide; Humans; Male; Middle Aged; Natriuretic Agents; Na | 2004 |
Effect of furosemide and weight carriage on energetic responses of horses to incremental exertion.
Topics: Animals; Carbon Dioxide; Energy Metabolism; Female; Furosemide; Horses; Lactates; Lactic Acid; Oxyge | 1993 |
Efficacy of albumin and diuretic therapy in children with nephrotic syndrome.
Topics: Adolescent; Albumins; Blood Pressure; Child; Child, Preschool; Female; Furosemide; Humans; Infant; I | 1993 |
Bioelectrical impedance analysis as an assessment of diuresis in congestive heart failure.
Topics: Administration, Oral; Aged; Body Composition; Body Water; Body Weight; Cohort Studies; Diuretics; El | 1995 |
[Simultaneous analysis of four diuretic drugs by HPLC and its application to health food supplements advertising weight reduction].
Topics: Chromatography, High Pressure Liquid; Dietary Supplements; Diuretics; Food, Organic; Furosemide; Sod | 2002 |
Furosemide-induced changes in plasma and blood volume of horses.
Topics: Animals; Blood Volume; Dye Dilution Technique; Female; Furosemide; Hematocrit; Hemoglobins; Horses; | 1991 |
Symptomatic patent ductus arteriosus in very-low-birth-weight infants: 1987-1989.
Topics: Analysis of Variance; Cardiac Surgical Procedures; Colloids; Ductus Arteriosus, Patent; Female; Flui | 1991 |
Ascitic fluid protein and cellular changes during diuretic therapy in cirrhosis of liver.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ascitic Fluid; Blood Proteins; Cell Count; Furosemide; H | 1991 |
Adverse effects of dietary and furosemide-induced sodium depletion on thermoregulation.
Topics: Animals; Body Temperature Regulation; Diet, Sodium-Restricted; Disease Models, Animal; Furosemide; H | 1990 |